Action Zymeworks - ZYME

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Dernier

15,25

Prix Achat

15,27

Prix Vente

15,96

Volume échangé

845 721

14,99 Fourchette du Jour 17,07

7,97 Plage de 52 semaines 17,70

Cap du marché

1,05B

Clôture Veille

14,78

Ouverture

16,46

Dernière Transaction

15.62

Dernière heure de transaction

Volume financier

US$ 13 179 593

VWAP

15,5839

Volume moyen (3 m)

501 994

Actions en circulation

68 877 526

Rendement du Dividende

Ratio Cours sur Bénéfices

-8,72

Bénéfice par action (BPA)

-1,72

Chiffre d'affairess

76,01M

Bénéfice net

-118,67M

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiat... Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its lead clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas. Show more

Secteur

Pharmaceutical Preparations

Industrie

Pharmaceutical Preparations

Site Web

www.zymeworks.com

Siège social

Wilmington, Delaware, USA

Fondé

Zymeworks Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker ZYME. Le dernier cours de clôture d'Zymeworks était de US$14,78. Au cours de la dernière année, les actions de Zymeworks ont été négociées dans une fourchette de prix de US$ 7,97 à US$ 17,70.

Zymeworks compte actuellement 68 877 526 actions en circulation. La capitalisation boursière d'Zymeworks est de US$1,02 milliard. Zymeworks a un ratio cours/bénéfice (ratio PE) de -8.72.

Form 4 - Statement of changes in beneficial ownership of securities

Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases

Company on track to deliver five Investigational New Drug (IND) applications as part of ‘5 by 5’ solid tumor strategy 18 months ahead of original targetNomination of ZW209, a novel trispecific T...

Form 8-K - Current report

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...

FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

Ziihera is the first and only dual HER2-targeted bispecific antibody approved for HER2-positive BTC in the U.S.Ziihera received accelerated approval based on results including a 52% objective...

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors

VANCOUVER, British Columbia, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0.73	5.02754820937	14.52	15.25	13.771	455158	14.61966218	CS
4	1.07	7.54583921016	14.18	15.25	12.43	525760	13.78775979	CS
12	2.45	19.140625	12.8	17.7	12.39	501994	14.29794074	CS
26	6.82	80.9015421115	8.43	17.7	8.32	612663	12.26656376	CS
52	4.85	46.6346153846	10.4	17.7	7.97	605491	11.11051126	CS
156	8.87	139.028213166	6.38	17.7	6.015	619939	9.63816715	CS
260	8.87	139.028213166	6.38	17.7	6.015	619939	9.63816715	CS

ZYME - Frequently Asked Questions (FAQ)

What is the current Zymeworks share price?

The current share price of Zymeworks is US$ 15,25

How many Zymeworks shares are in issue?

Zymeworks has 68 877 526 shares in issue

What is the market cap of Zymeworks?

The market capitalisation of Zymeworks is USD 1,02B

What is the 1 year trading range for Zymeworks share price?

Zymeworks has traded in the range of US$ 7,97 to US$ 17,70 during the past year

What is the PE ratio of Zymeworks?

The price to earnings ratio of Zymeworks is -8,72

What is the cash to sales ratio of Zymeworks?

The cash to sales ratio of Zymeworks is 13,62

What is the reporting currency for Zymeworks?

Zymeworks reports financial results in USD

What is the latest annual turnover for Zymeworks?

The latest annual turnover of Zymeworks is USD 76,01M

What is the latest annual profit for Zymeworks?

The latest annual profit of Zymeworks is USD -118,67M

What is the registered address of Zymeworks?

The registered address for Zymeworks is CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801

What is the Zymeworks website address?

The website address for Zymeworks is www.zymeworks.com

Which industry sector does Zymeworks operate in?

Zymeworks operates in the PHARMACEUTICAL PREPARATIONS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
FCUVFocus Universal Inc	US$ 0,9499 (174,93%)	260,93M
NITON2OFF Inc	US$ 2,6306 (145,85%)	358,28M
CRNCCerence Inc	US$ 19,33 (143,76%)	161,8M
KITTNauticus Robotics Inc	US$ 3,8249 (140,56%)	104,8M
ACONAclarion Inc	US$ 0,2984 (110,14%)	305,64M
HWHHWH International Inc	US$ 0,4621 (-28,80%)	7,43M
SMSTDefiance Daily Target 2x Short MSTR ETF	US$ 5,69 (-26,30%)	24,77M
RAINRain Enhancement Technologies Holdco Inc	US$ 5,59 (-23,42%)	161,15k
PTLEPTL Ltd	US$ 9,35 (-23,30%)	1,04M
NXUNXU Inc	US$ 0,725868 (-22,78%)	7,59M
NITON2OFF Inc	US$ 2,6306 (145,85%)	358,28M
TGLTreasure Global Inc	US$ 0,382 (101,58%)	337,5M
ACONAclarion Inc	US$ 0,2984 (110,14%)	305,64M
FCUVFocus Universal Inc	US$ 0,9499 (174,93%)	260,93M
NVDANVIDIA Corporation	US$ 144,47 (4,45%)	230,01M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Zymeworks Inc (ZYME)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

À propos de Zymeworks Inc

ZYME Dernières nouvelles

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases

Form 8-K - Current report

Form 8-K - Current report

Zymeworks Announces Participation in Upcoming Investor Conferences

FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases

Form 8-K - Current report

Form 8-K - Current report

Zymeworks Announces Participation in Upcoming Investor Conferences

FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

ZYME - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Zymeworks Inc (ZYME) Cours

Zymeworks Inc (ZYME)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

À propos de Zymeworks Inc

ZYME Dernières nouvelles

ZYME - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application